COMPANY

Benitec Biopharma

HQ: Hayward, CA source · benitec.com ↗ · West Coast

Location: Hayward, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Oculopharyngeal Muscular Dystrophy Head and Neck Squamous Cell Carcinoma BB-401

Timeline

Nov 5, 2025 Raise Follow-on offering: $100M (total, as published), announced Nov 5, 2025. Source: SEC filing. source ↗
Mar 25, 2025 Raise Follow-on offering: $30M (total, as published), announced Mar 25, 2025. Source: SEC filing. source ↗
Nov 28, 2023 Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia source ↗
Mar 15, 2018 Trial start Phase 2: A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma source ↗

2030-11 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia · NCT06185673

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $130.0M. Last 2 years.

Nov 5, 2025 Follow-on offering: $100M (total, as published), announced Nov 5, 2025. Source: SEC filing. source ↗
Mar 25, 2025 Follow-on offering: $30M (total, as published), announced Mar 25, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06185673	A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia	Phase 1/Phase 2	Recruiting	Nov 28, 2023	2030-11 (estimated)
NCT03433027	A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Phase 2	Completed	Mar 15, 2018	Dec 12, 2018 (actual)